Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer https://pharmadevicenews.com/frontier-to-reveal-first-fmc-376-clinical-responses-in-kras-g12c-lung-cancer/ @FrontierMeds will disclose the first human data for FMC-376 on October 25, including tumor responses in patients previously treated with KRAS G12C inhibitors. Unlike established OFF-state inhibitors, FMC-376 is designed to target both active and inactive KRAS G12C. The key question is whether this dual mechanism can produce durable responses without unacceptable toxicity. #FrontierMedicines #FMC376 #ESMO2026 #KRASG12C #LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #ClinicalTrials #Biotechnology